Ertapenem Sodium

Tier C — Watch / trade

Ertapenem Sodium

Merck & Co Inc

Originator

2001

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：PBPs

Brand：Invanz

Indications (approved)：Complicated skin and skin structure infection, Intra-abdominal infection, Bacteraemia, Urinary tract infection, Community-acquired pneumonia, Pyelonephritis, Bacterial infection, Gram-negative bacterial infection

Regional status

Approved

2001-11-21

Approved

2002-04-18

China

Approved

2005-09-12

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Ertapenem Sodium?

Approved indications include: Complicated skin and skin structure infection, Intra-abdominal infection, Bacteraemia, Urinary tract infection, Community-acquired pneumonia, Pyelonephritis, Bacterial infection, Gram-negative bacterial infection.

When does the Ertapenem Sodium patent expire?

No public expiry year is available for Ertapenem Sodium yet; this page updates once verified.

How do I get a quote for Ertapenem Sodium intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27